The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer.
Daniel J Zabransky; Heath A Smith; Christopher J Thoburn; Marianna Zahurak; Daniel Keizman; Michael Carducci; Mario A Eisenberger; Douglas G McNeel; Charles G Drake; Emmanuel S Antonarakis (Profiled Authors: Michael Carducci; Mario Eisenberger; Charles Drake)
Johns Hopkins Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
The Prostate 2012;72(5):487-98.
BACKGROUND: We retrospectively explored changes in immunological parameters in men with biochemically recurrent prostate cancer treated with either 5 or 25 mg of lenalidomide in a randomized phase 2 trial, and determined whether those changes correlated with disease progression. METHODS: Cytokine levels were compared for each patient at baseline and after 6 months of treatment with lenalidomide. Regression models for correlated data were used to assess associations of cytokine levels with lenalidomide treatment effect. Estimates were obtained using generalized estimating equations. Changes in circulating anti-prostate antibodies were evaluated using a high-throughput immunoblot technique. RESULTS: Treatment with lenalidomide was associated with global changes in immunoreactivity to a number of prostate-associated antigens, as well as with changes in circulating levels of the T(H) 2 cytokines IL-4, IL-5, IL-10, and IL-13. Disease progression in treated patients was associated with an increase in circulating IL-8 levels, while IL-8 levels decreased significantly in non-progressors. CONCLUSIONS: Lenalidomide demonstrates immunomodulatory properties in patients with biochemically recurrent prostate cancer. The induction of novel anti-prostate antibodies is a potential mechanism for lenalidomide response. Changes in serum IL-8 levels may serve as a potential biomarker in treated patients. These hypotheses require formal testing in future prospective trials.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Masood A Khan; Alan W Partin; Leslie A Mangold; Jonathan I Epstein; Patrick C WalshUrology 2003;62(5):866-71.
Daniel Keizman; Marianna Zahurak; Victoria Sinibaldi; Michael Carducci; Samuel Denmeade; Charles Drake; Roberto Pili; Emmanuel S Antonarakis; Susan Hudock; Mario EisenbergerClinical cancer research : an official journal of the American Association for Cancer Research 2010;16(21):5269-76.
Ai-Ying Chuang; Matthew E Nielsen; David J Hernandez; Patrick C Walsh; Jonathan I EpsteinThe Journal of urology 2007;178(4 Pt 1):1306-10.
Appears in this Publication
Author of this Publication